title: Auditory effects after organ preservation protocol for laryngeal/hypopharyngeal carcinomas.
abstract: OBJECTIVE
  To investigate the prevalence of hearing loss after concomitant radiochemotherapy in patients enrolled in a larynx preservation protocol.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Consecutive patients treated in a tertiary cancer center hospital between 2001 and 2002.
  
  
  METHODS
  Eligible subjects included patients prospectively enrolled in an organ preservation protocol based on concomitant radiotherapy and chemotherapy (cisplatin and paclitaxel).
  
  
  METHODS
  Descriptive analysis of the results of audiologic evaluations, including pure-tone audiometry and immitance audiometry, which were performed prior to and 8 months after treatment. Change in hearing sensitivity was computed relative to baseline measures. Criteria to indicate hearing decrease after the treatment were defined as either a 20-dB decrease at any single test frequency or a 10-dB decrease at any 2 adjacent test frequencies.
  
  
  RESULTS
  A total of 11 patients were analyzed. Four patients (36%) had hearing loss after the treatment.
  
  
  CONCLUSIONS
  Our results suggest that the prevalence of hearing loss after radiochemotherapy in larynx preservation protocols is high (36%); however, it was usually mild and asymptomatic.
authors.affiliation: Department of Audiology, Hospital do Câncer A.C. Camargo, São Paulo, Brazil.
authors.forename: Patricia Helena Pecora
authors.initials: PH
authors.lastname: Liberman
authors.forename: Christiane
authors.initials: C
authors.lastname: Schultz
authors.forename: M Valéria Schmidt Goffi
authors.initials: MV
authors.lastname: Gomez
authors.forename: André Lopes
authors.initials: AL
authors.lastname: Carvalho
authors.forename: Antonio Cassio Assis
authors.initials: AC
authors.lastname: Pellizzon
authors.forename: José Ricardo
authors.initials: JR
authors.lastname: Testa
authors.forename: Olavo
authors.initials: O
authors.lastname: Feher
authors.forename: Luiz Paulo
authors.initials: LP
authors.lastname: Kowalski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006319:Hearing Loss, Sensorineural / Q000209:etiology*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin